$VERX

Vertex Raises Profit Outlook as Cloud Revenue Climbs 18%

Vertex (NASDAQ: VERX) raised its 2026 adjusted EBITDA outlook to $206M-$210M after Q2 revenue rose 10.5% to $204M and cloud revenue grew 17.9% to $101.7M. Full-year revenue guidance was narrowed to $825M-$830M, with 18% cloud growth expected. Q2 adjusted EBITDA rose 32.8% to $51M.

Original reporting
Published Aug 10, 2026, 7:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vertex Raises Profit Outlook as Cloud Revenue Climbs 18% — source image
Decision brief

The 30-second read

$VERXBullishMed
01

Why it matters

Traders can reprice the stock based on the updated full-year ranges and the stated expectation of expanding profitability and stronger cash generation in Q3 and Q4, while monitoring GAAP loss and retention trends.

02

Market read

Raised 2026 adjusted EBITDA and revenue guidance, supported by nearly 18% cloud growth, is a concrete catalyst for repricing recurring-software profitability expectations.

03

What to watch

The company cannot reconcile adjusted EBITDA to GAAP net income due to unpredicted items, which may increase uncertainty around how much of the EBITDA improvement translates to GAAP earnings.

Relevance 8/10Novelty 8/10Timing: after-hours/next-session positioning following raised 2026 guidance

Background

Vertex reported Q2 results with revenue growth and strong cloud expansion, then revised its 2026 adjusted EBITDA and revenue outlook.

Company-level read

Ticker impact

$VERXBullishMedium confidence
Context

Vertex raised full-year adjusted EBITDA outlook to $206M-$210M and kept 18% cloud revenue growth as Q2 cloud sales rose 17.9%.

Expected impact

Bias toward higher shares on guidance credibility, with volatility risk if GAAP loss trajectory or retention metrics deteriorate.

Evidence & confidence

The article discloses specific updated financial guidance (EBITDA range, revenue range) plus Q2 operating metrics (cloud growth, adjusted EBITDA margin expansion). It also flags GAAP operating loss widening and retention down, which can temper the reaction.

Market effects

Signals continued demand strength in tax software cloud offerings and potential margin expansion for recurring-revenue software peers.

Limited, company-specific US software update.

Low, no cross-border deal or macro policy linkage described.

Counterpoint

GAAP operating loss widened and net revenue retention fell to 105% from 108%, so the quality of growth and durability of profitability could be questioned.

Key entities

  • Vertex, Inc.

    Tax software company raising 2026 adjusted EBITDA outlook and projecting continued 18% cloud revenue growth.

  • John Schwab

    CFO cited first-half performance and operating model for the revised outlook.

  • Christopher Young

    CEO discussed improved electronic invoicing demand and an AI-First strategy.

Related articles

$VERXMedAI 8/10

Vertex (VERX) Q2 2026 Earnings Call Transcript

Vertex, Inc. (VERX) reported Q2 2026 revenue of $204 million, up 10.5% year over year and at the high end of guidance. Adjusted EBITDA rose 33% to $51 million, with margin expanding to 25.0%. Subscription revenue grew to $174.8 million and ARR reached $703.4 million. Full-year revenue guidance was narrowed to $825-$830 million and adjusted EBITDA guidance raised to $206-$210 million.

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.